Subcutaneous depo-medroxyprogesterone acetate.

Concentration Changes of Medroxyprogesterone Acetate in Serum and Milk in Lactating Woman Who Used Depo Geston®

Objective To determine the concentration changes of medroxyprogesterone acetate (MPA) in serum and milk in the Chinese lactating women who used Depo Geston® Methods Ten postpartum and breastfeeding women received an injectable contraceptive of Depo Geston® (depo medroxyprogesterone acetate,DMPA, 150 mg/ampoule). Serum and milk samples were collected in the 1st, 2nd, 4th, 6th, 8th 10th and 12th ...

Medroxyprogesterone acetate [Depo Provera] injections. Development of striae.

A young girl developed extensive striae while on Depo Provera injections. She had gained some weight during the treatment. Endocrinal investigations were negative. The development of striae was attributed to her weight gain.

Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss.

Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer.

OBJECTIVE To determine whether use of the injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera) affects the risk of breast cancer in women. DESIGN A population based case-control study. SETTING Nationwide community study. SUBJECTS 891 Women aged 25-54 with newly diagnosed breast cancer were compared with 1864 women selected at random from the electoral rolls. INTERVE...

Treatment of sex offenders with Depo-Provera.

Medroxyprogesterone acetate (MPA) is capable of reducing male testosterone blood levels with a corresponding reduction in sexual interest and activity. An attempt to evaluate its effectiveness with court committed sexual offenders was made with eight subjects each serving as his own control by alternating Depo-Provera injections for 16 weeks with saline injections for a corresponding 16 weeks. ...